Several oncogenic pathway inhibitors are currently undergoing clinical trial evaluation in sarcoma including drugs targeting the PI3K/mTOR (deferolimus and everolimus), Src (dasatinib and AZD0530), and the Ras/Raf pathway (sorafenib). Here, SRC is linked to sarcoma.